Latest Research News

Get the most up-to-date Research news related to Scleroderma and Raynaud's

News article - Celebrating World Clinical Trials Day!

20 May 2021 is World Clinical Trials Day to mark the anniversary of the first-ever trial that was conducted in 1747. Today, clinical trials are vital in determining the safety and efficacy of new treatments all over the world. But what happens in a clinical trial, and could you take part?
Find out more

News article - Your Raynaud’s and You – Insights from SRUK’s work on the Raynaud’s App

Can you imagine a world where we could have a greater understanding of Raynaud’s? Have more information on what triggers an attack? Understand how in some cases Raynaud’s combined with other symptoms may be an early predictor of scleroderma? The Raynaud’s ResearchApp, an SRUK-led partnership with app development company Healthbit and data company D4T4, intends to do just this!
Find out more

News article - The Raynaud’s App: the story so far

SRUK is pioneering ‘The Raynaud’s ResearchApp,’ that aims to help identify Raynaud’s patients at risk of developing scleroderma, with a view to achieving earlier diagnosis and improved outcomes. The technology also enables users to record their experiences of Raynaud’s symptoms and learn more about potential triggers. The App has recently been piloted in a clinical trial.
Find out more

News article - A Design for Life: is scleroderma in the genes?

What is the link between our genetic code and developing scleroderma? Researchers from Spain have recently studied genetic alterations and established a connection with the pathways that dictate the clinical features of scleroderma. The study is significant because increasing our understanding of the genetic pathway could be a faster route towards identifying effective new therapies for this complex condition.
Find out more

News article - Open Research - revolutionising the publishing process for SRUK research

SRUK is working with our partners at the Association of Medical Research Charities via their new Open Research Platform, to revolutionise the publishing process for our researchers. This will enable SRUK-funded research groups to publish their work in a streamlined and cost-effective way, with the ultimate goal of translating new knowledge into effective treatments for people living with scleroderma.
Find out more

News article - What's the outcome? Measuring the effectiveness of new treatments in clinical trials

Clinical trials are the only way to ensure that new treatments are effective. But how exactly does the process work? FInd out why 'outcome measures’ and ‘endpoints’ are crucial, and how SRUK funding is playing a key role in improving the measures used in treatments for scleroderma.
Find out more

News article - The Link Between Metabolism and Fibrosis in People With Scleroderma

A new study from the UK has identified a possible connection between metabolism and fibrosis in people with scleroderma, with the potential to open up new treatment avenues in the future.
Find out more

News article - SRUK’s co-funded project with World Scleroderma Foundation seeking to improve the Combined Response Index in SSc Score.

An important part of participating in a project such as this is ensuring that you understand how the collected data will be used and why community input is so valuable and fundamentally vital.
Find out more

News article - Findings of nintedanib's safety and tolerability published

A team of researchers based in the USA, UK, Germany, Switzerland and Japan sought to examine the results of the SENSCIS trial to assess the safety and tolerability of nintedanib in people with SSc-ILD.
Find out more

News article - The CRISTAL Index

SRUK funding is playing a key role in improving how we determine the success of new treatments in clinical trials. These projects aim to better inform researchers of the impact of potential therapies, ultimately improving wellbeing and quality of life for people living with scleroderma.
Find out more

News article - Collaboration is Key: Developing a New Diagnostic Tool for Scleroderma

“We are limited by current assessment tools such as the skin score, which is limited by subjectivity, as well as the time needed for training and standardisation. We need to make sure that new treatments are evaluated in the best and most robust way so that we can make more progress and discontinue approaches that do not work.” Prof. Chris Denton
Find out more

News article - Touching on Touchscreens - Making Technology More Accessible for People With Scleroderma

Are you reading this from a touchscreen device? Using touchscreen technology is something many of us do every day, without even thinking about it. But what happens to the people who have conditions that make touchscreens tough?
Find out more